• MT Pharma America's Radicava secures FDA approval to treat ALS pharmaceutical-technology
    May 10, 2017
    MT Pharma America has secured the US Food and Drug Administration (FDA) approval for Radicava (edaravone) as an intravenous infusion treatment for patients affected with amyotrophic lateral sclerosis (ALS).
  • FDA approves drug to treat ALS worldpharmanews
    May 08, 2017
    The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease.
  • Could Electromagnetic Fields Raise a Worker's ALS Risk? drugs
    March 30, 2017
    On-the-job exposure to electromagnetic fields may double the risk of developing amyotrophic lateral sclerosis (ALS), a degenerative disease of the nervous system, a new study suggests.
PharmaSources Customer Service